Landos Biopharma Inc expected to post a loss of 9 cents a share - Earnings Preview

Landos Biopharma

08/05/2023 13:02

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show no
change in quarterly revenue when it reports  results on May 10
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Landos Biopharma
Inc is
for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $1.05​, above​ its last closing price of $0.29. ​​​

This summary was machine generated May 8 at 12:02 GMT.  All
figures in US dollars  unless otherwise stated